COMMUNIQUÉS West-GlobeNewswire
-
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
14/09/2026 -
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
14/09/2026 -
Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network
14/09/2026 -
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
14/09/2026 -
Quiet Communities and Science for Georgia Release First-of-its-Kind Study on the Impacts of Data Center and Cryptomining Noise
14/09/2026 -
KFSH Riyadh Records Zero High-Risk Findings Across Nearly 1,800 Measures in JCI Reaccreditation
14/09/2026 -
GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
14/09/2026 -
GENFIT engage un programme de développement clinique de phase 2 avec Nangibotide dans l’ACLF
14/09/2026 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026
14/09/2026 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2026
14/09/2026 -
Paralyzed Marine Veteran Stands and Walks at Enjoy Illinois 300 as Patriot Mobile Puts SoldierStrong on Ty Dillon's No. 10
14/09/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
14/09/2026 -
Wellthy Acquires Cleo as Two Leaders Come Together to Create the Singular Platform for Family Care
14/09/2026 -
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
14/09/2026 -
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
14/09/2026 -
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
14/09/2026 -
Leios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullness
14/09/2026 -
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
14/09/2026 -
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
14/09/2026
Pages